{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:03:25Z","timestamp":1791864205164,"version":"4.3.4"},"reference-count":29,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>This study aimed to compare the prognosis of patients with chronic lymphocytic leukemia (CLL) harboring TP53 abnormalities or a complex karyotype who are refractory to a covalent Bruton kinase inhibitors (cBTKi) or B-cell lymphoma 2 inhibitors (BCL2i; single-refractory high-risk [SRHR] genetics) with that of patients refractory to both cBTKi and BCL2i (double-refractory [DR]), and to investigate the outcome of allogeneic hematopoietic cell transplantation (alloHCT) in these settings. Overall, 47 patients were included. Of these, 40 patients entered the study in SRHR status, and 7 patients in DR status. Because 17 patients evolved from having SRHR to DR status over time, the total DR population comprised 24 patients. In the SRHR cohort, 78% had cBTKi-refractory and 22% had BCL2i-refractory disease, and TP53 abnormalities were in present in 90% of the patients with SRHR. Median event-free survival (defined as progression on next line, or death) of the SRHR cohort was 22 months; and median overall survival (OS) of the SRHR and DR cohorts was 51 and 21 months, respectively. A total of 22 patients underwent alloHCT; their nonrelapse mortality, relapse incidence, progression-free survival, and OS at 2 years was 19%, 19%, 62%, and 67%, respectively. Although long-term progression-free survivors were observed after transplantation, exploratory comparisons of patients who received a transplant and those who did not did not show a significant OS benefit in favor of alloHCT. In conclusion, the outlook of patients with high-risk single-refractory CLL is dismal but better than in patients with DR disease. In both settings, alloHCT is feasible and may overcome clinical and biological disease refractoriness; however, its exact benefit and timing remain to be determined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020219","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:02:17Z","timestamp":1781301737000},"page":"5698-5705","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-0167","authenticated-orcid":false,"given":"Joseph","family":"Kauer","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1667-4109","authenticated-orcid":false,"given":"Isabelle","family":"Kr\u00e4mer","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-8851","authenticated-orcid":false,"given":"Patrick","family":"Derigs","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7524-4080","authenticated-orcid":false,"given":"Maximilian Felix","family":"Blank","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"2Department of Hematology, Oncology and Clinical Immunology, Center of Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University Hospital D\u00fcsseldorf, Heinrich-Heine-University, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Meissner","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Kehl","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6401-3623","authenticated-orcid":false,"given":"Mirco Julian","family":"Friedrich","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7853-4465","authenticated-orcid":false,"given":"Maria-Luisa","family":"Schubert","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1656-0833","authenticated-orcid":false,"given":"Anthony Dick","family":"Ho","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Schmitt","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Oncology and Clinical Immunology, Center of Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University Hospital D\u00fcsseldorf, Heinrich-Heine-University, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1579-1509","authenticated-orcid":false,"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"5","key":"2026082510522842800_bib1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/bloodadvances.2024014474","article-title":"Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL","volume":"9","author":"Soumerai","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"2026082510522842800_bib2","first-page":"494","article-title":"Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular Therapy","volume":"31","author":"Kharfan-Dabaja","year":"2025","journal-title":"Cell Ther"},{"issue":"17","key":"2026082510522842800_bib3","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2024025482","article-title":"How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor","volume":"146","author":"Shadman","year":"2025","journal-title":"Blood"},{"issue":"2","key":"2026082510522842800_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood.2024024893","article-title":"Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia","volume":"146","author":"Grainger","year":"2025","journal-title":"Blood"},{"key":"2026082510522842800_bib5","author":"Sureda","year":"2024"},{"issue":"6","key":"2026082510522842800_bib6","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1111\/bjh.70100","article-title":"2025 British Society for Haematology guideline for the treatment of chronic lymphocytic leukaemia","volume":"207","author":"Walewska","year":"2025","journal-title":"Br J Haematol"},{"issue":"20","key":"2026082510522842800_bib7","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"2026082510522842800_bib8","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/bloodadvances.2025016006","article-title":"Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia","volume":"9","author":"Yoon","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"2026082510522842800_bib9","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/bloodadvances.2023011327","article-title":"Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon","volume":"8","author":"Lew","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026082510522842800_bib10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties","volume":"54","author":"Dreger","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"16","key":"2026082510522842800_bib11","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"issue":"17","key":"2026082510522842800_bib12","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/bloodadvances.2020002184","article-title":"Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia","volume":"4","author":"Kim","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2026082510522842800_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41409-025-02522-4","article-title":"Intermediate-dose TBI\/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma","volume":"60","author":"Kramer","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2026082510522842800_bib14","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41375-024-02392-7","article-title":"Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: a phase 1\/2 study","volume":"38","author":"Derigs","year":"2024","journal-title":"Leukemia"},{"key":"2026082510522842800_bib15","unstructured":"S3-Leitlinie Chronische lymphatische Leuk\u00e4mie\n          . . Accessed 10 February 2026. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/CLL\/Version_2\/LL_CLL_Langversion_2.0.pdf."},{"issue":"5","key":"2026082510522842800_bib16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/10428194.2023.2190436","article-title":"Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study","volume":"64","author":"Eyre","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"2026082510522842800_bib17","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO-25-00166","article-title":"Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"13","key":"2026082510522842800_bib18","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"issue":"14","key":"2026082510522842800_bib19","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1158\/1078-0432.CCR-09-0199","article-title":"Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia","volume":"15","author":"Nishida","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026082510522842800_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdt511","article-title":"The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison","volume":"25","author":"Herth","year":"2014","journal-title":"Ann Oncol"},{"issue":"12","key":"2026082510522842800_bib21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2017-04-775841","article-title":"Allogeneic hematopoietic stem cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial","volume":"130","author":"Kr\u00e4mer","year":"2017","journal-title":"Blood"},{"issue":"561","key":"2026082510522842800_bib22","doi-asserted-by":"crossref","first-page":"eabb7661","DOI":"10.1126\/scitranslmed.abb7661","article-title":"Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect","volume":"12","author":"Bachireddy","year":"2020","journal-title":"Sci Transl Med"},{"issue":"1","key":"2026082510522842800_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2141.2012.09239.x","article-title":"Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia","volume":"159","author":"Jaglowski","year":"2012","journal-title":"Br J Haematol"},{"issue":"10402","key":"2026082510522842800_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"22","key":"2026082510522842800_bib25","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1182\/bloodadvances.2023011399","article-title":"Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed\/refractory CLL","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2026082510522842800_bib26","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood.2024027460","article-title":"ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"146","author":"Davids","year":"2025","journal-title":"Blood"},{"key":"2026082510522842800_bib27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hon.70093_144","article-title":"Updated efficacy\/safety of the BTK degrader BGB-16673 in relapsed\/refractory CLL\/SLL: results from the ongoing phase 1 CaDAnCe-101 study [abstract]","volume":"43","author":"Seymour","year":"2025","journal-title":"Hematol.Oncol"},{"issue":"1","key":"2026082510522842800_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1182\/hematology.2024000570","article-title":"Relapsed\/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagers","volume":"2024","author":"Kater","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"2026082510522842800_bib29","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2352-3026(25)00327-8","article-title":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial","volume":"13","author":"Kater","year":"2026","journal-title":"Lancet Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5698\/2538173\/blooda_adv-2026-020219-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5698\/2538173\/blooda_adv-2026-020219-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:58:32Z","timestamp":1787669912000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/16\/5698\/569120\/High-risk-single-refractory-and-double-refractory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":29,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020219","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,25]]},"published":{"date-parts":[[2026,8,17]]}}}